Background Most patients with metastatic cancer eventually develop resistance to systemic
therapy, with some having limited disease progression (ie, oligoprogression). We aimed to …

Simple Summary Several retrospective studies present evidence of oligoprogressive
disease (OPD) in patients with non-small cell lung cancer (NSCLC) with driver mutations …

Background Despite the paucity of prospective evidence, stereotactic radiotherapy (SRT) is
increasingly being considered in the setting of oligoprogression to delay the need to change …

Purpose The objective of this study was to describe the patterns of failure, frequency of low-
volume relapse (LVR), and candidacy for ablative therapy at time of disease progression …

Introduction The patterns of failure (POF) for metastatic non–small-cell lung cancer
(mNSCLC) treated with immunotherapy are not well established. Methods We conducted a …

Objectives To investigate the feasibility and potential clinical value of local consolidative
therapy (LCT) in PD-1/PD-L1 inhibitor-treated metastatic non-small cell lung cancer …

Recent advances in targeted therapies have made significant progress in improving survival
outcomes in patients with many types of cancer. In non-small cell lung cancer (NSCLC) …

Background Stereotactic body radiotherapy (SBRT) is increasingly used to treat
oligometastatic disease (OMD), but the effect of metastasis timing on patient outcomes …

Objectives This retrospective study investigated prognostic factors in advanced non-small
cell lung cancer (NSCLC) with bone-only metastasis, and developed a graded prognostic …

Background Oligoprogression (OPD) is defined as a condition where limited progression (1–
3 metastases) is observed in patients undergoing systemic cancer treatment. In this study we …